Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth-containing quadruple therapy for H. pylori first-line treatment
NCT02732249Phase 4Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Apr 2016
- Primary completion
- Sep 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bismuth subcitrate in Helicobacter pylori infection (3 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Helicobacter pylori eradication rate at 6 weeks. Started Apr 2016; status: completed.
02
Drugs
bismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT02732249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02732249.